Hematological Care Team
The Hematological Care Team at the University of Virginia seeks to provide state-of-the-art care to patients with all forms of hematologic malignancy and to offer cutting-edge therapies while maximizing disease response and cure. The Hematologic Malignancy Team specializes in cancers of the blood and lymphatic systems, including acute and chronic leukemias, Hodgkin's lymphoma, non-Hodgkin's lymphoma, mycosis fungoides, multiple myeloma, Sezary syndrome, cutaneous cancer, and Waldenström's Macroglobulinemia. Consultations and primary management are provided through our Cancer Center clinics, with comprehensive management decisions reviewed in our weekly Hematologic Malignancy Tumor Board meetings that include clinician, hematopathologist and cytogeneticist contributions. The services of social workers, psychologists, and patient support groups are also available.
Dramatic advances have been made in recent years for many of these disorders, arising from new insights into their molecular biology and the application of novel targeted therapies, which complement or replace traditional chemotherapeutic and radiotherapy approaches. Clinical trials are offered for many disorders, with a special focus on monoclonal antibody, vaccine and novel targeted therapy approaches.
The Hematologic Malignancy Team is part of the University of Virginia Cancer Center, which is a highly-ranked National Cancer Institute designated Cancer Center